Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Lodges Patent for Major Septic Shock Opportunity

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce lodgement of an international patent application aimed at protecting the use of Veyonda (idronoxil) in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.

Veyonda is being developed as an anti-cancer drug that enhances the effectiveness of standard anticancer treatments. One of its anti cancer actions is the blocking of a signalling pathway called STING that serves as trigger for an immune response and repair of damaged tissue. In some individuals, the STING response is inappropriately excessive, pushing the individual over into septic shock.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.